Fenofibrate

Revision as of 22:01, 31 August 2017 by ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antihyperlipidemic *Dosage Forms: *Routes of Administration: oral *Common Trade Names: ==Adult Dosing== *40-160mg PO daily ==Pediatric Dosing== ''...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Antihyperlipidemic
  • Dosage Forms:
  • Routes of Administration: oral
  • Common Trade Names:

Adult Dosing

  • 40-160mg PO daily

Pediatric Dosing

Safety/efficacy not established

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: infant risk has been demonstrated
  • Renal dosing: contraindicated in severe impairement
  • Hepatic dosing: contraindicated in active liver disease, primary biliary cirrhosis, or unexplained persistent liver function abnormalities

Contraindications

  • Allergy to class/drug
  • Active liver or gallbladder disease
  • Severe renal impairment
  • Nursing mothers

Adverse Reactions

Serious

  • Pancreatitis
  • Cholestatic hepatitis
  • Rhabdomyolysis
  • Raised serum creatinine

Common

  • Abdominal pain, nausea
  • Abnormal LFTs
  • Backache
  • Rhinitis

Pharmacology

  • Half-life: 10-30h
  • Metabolism:
  • Excretion: Mostly renal

Mechanism of Action

  • Increases lipolysis and elimination of triglyceride-rich particles from plasma via activation of peroxisome proliferator-activated receptor alpha

Comments

See Also

References

Retrieved from "https://www.wikem.org/w/index.php?title=Fenofibrate&oldid=154006"
Authors: